肿瘤浸润淋巴细胞（TILs）与抗 PD-1 治疗：PDL1 阴性转移性宫颈癌的一种替代联合治疗方法。
TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.
机构信息
Department of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, China.
出版信息
J Immunol Res. 2020 Sep 7;2020:8345235. doi: 10.1155/2020/8345235. eCollection 2020.
BACKGROUND
We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative.
METHODS
A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and overall survival time (OS) were assessed by Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify factors that could predict the prognosis of metastatic cervical cancer in the previously described patients.
RESULTS
The objective response rate was 25%, whereas the mPFS and mOS were 6.1 and 11.3 months, respectively. The therapeutic efficacy was influenced by the characteristics of TILs, infection with HPV, and development of fever just after the therapy.
CONCLUSION
Overall, our results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer.
背景
我们研究了 TILs 和抗 PD1 联合治疗在低 MSI 表达和 PDL1 阴性的转移性宫颈癌患者中的疗效。
方法
共 80 例患者接受 TILs 和抗 PD1 联合治疗，采用 Kaplan-Meier 分析评估无进展生存期（PFS）和总生存期（OS）。对单因素和多因素分析以确定先前描述的转移性宫颈癌患者预后的预测因素。
结果
客观缓解率为 25%，mPFS 和 mOS 分别为 6.1 个月和 11.3 个月。治疗效果受 TILs 的特征、HPV 感染以及治疗后发热的影响。
结论
总的来说，我们的结果表明 TILs 和抗 PD1 的联合治疗显著改善了转移性宫颈癌的预后。
Zotero 插件